MiMedx Group, Inc. (MDXG)

Over the past six months, MiMedx Group's stock price has experienced a significant decline. Key events impacting the stock price include the announcement of record fourth-quarter and full-year 2025 results in February, the launch of AMNIOFIX® Thyroid Shields in March, and the launch of CHORIOFIX™ also in March. The stock also saw increases after hours following the announcement of record revenue for the third quarter of 2025 and record second-quarter 2025 operating and financial results.

The provided information does not contain specific details regarding the demand seasonality for MiMedx Group, Inc.'s products and services. However, one source mentions that Free Cash Flow (FCF) margin varies seasonally.

MiMedx Group, Inc. is a biomedical company specializing in regenerative biomaterial products and bioimplants derived from human placental tissues. The company operates within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. MiMedx utilizes its patented PURION process to create allografts. The product portfolio includes Wound Care Products like EPIFIX and Surgical and Other Products like AMNIOFIX, used in various surgical settings.

MiMedx Group, Inc. is headquartered in Marietta, Georgia, United States. The company primarily sells its products through a direct sales force and independent sales agents in the United States, with anticipated expansion into other geographies, particularly Japan.

MiMedx has a history of overcoming significant challenges, including financial difficulties due to allegations of mismanagement from 2016-2019. A new management team worked to resolve legal and financial issues and relisted on NASDAQ in October 2020, emphasizing transparency. MiMedx has been focused on advancing clinical and scientific evidence to support its placental tissue products.

The ownership structure of MiMedx Group is a mix of institutional, retail, and individual investors. Institutions possess a significant portion of the company's shares. The general public holds approximately 28% of the company's shares. Insiders own some shares in MiMedx Group.